Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1920 2
1921 4
1922 1
1963 1
1964 1
1967 6
1968 4
1969 3
1970 6
1971 3
1972 4
1973 2
1974 3
1975 5
1976 3
1977 9
1978 7
1979 8
1980 10
1981 23
1982 9
1983 14
1984 22
1985 8
1986 14
1987 18
1988 26
1989 26
1990 19
1991 15
1992 34
1993 24
1994 26
1995 30
1996 36
1997 43
1998 42
1999 41
2000 42
2001 47
2002 54
2003 46
2004 55
2005 62
2006 49
2007 42
2008 63
2009 84
2010 89
2011 95
2012 116
2013 88
2014 72
2015 61
2016 72
2017 79
2018 49
2019 56
2020 74
2021 88
2022 98
2023 79
2024 71
2025 85
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,188 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. Bassetti M, et al. Among authors: doi y. Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058795 Clinical Trial.
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study.
Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, Herc E, Alenazi T, Kaye KS, Garcia-Diaz J, Li L, Kanj SS, Liu Z, Oñate JM, Salata RA, Marimuthu K, Gao H, Zong Z, Valderrama-Beltrán SL, Yu Y, Tambyah P, Weston G, Salcedo S, Abbo LM, Xie Q, Ordoñez K, Wang M, Stryjewski ME, Munita JM, Paterson DL, Evans S, Hill C, Baum K, Bonomo RA, Kreiswirth BN, Villegas MV, Patel R, Arias CA, Chambers HF, Fowler VG Jr, Doi Y, van Duin D, Satlin MJ; Antibacterial Resistance Leadership Group and Multi-Drug Resistant Organism Network Investigators. Reyes J, et al. Among authors: doi y. Lancet Microbe. 2023 Mar;4(3):e159-e170. doi: 10.1016/S2666-5247(22)00329-9. Epub 2023 Feb 9. Lancet Microbe. 2023. PMID: 36774938 Free PMC article.
Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions.
Wang M, Ge L, Chen L, Komarow L, Hanson B, Reyes J, Cober E, Alenazi T, Zong Z, Xie Q, Liu Z, Li L, Yu Y, Gao H, Kanj SS, Figueroa J, Herc E, Cordova E, Weston G, Ananth Tambyah P, Garcia-Diaz J, Kaye KS, Dhar S, Munita JM, Salata RA, Vilchez S, Stryjewski ME, Villegas Botero MV, Iovleva A, Evans SR, Baum K, Hill C, Kreiswirth BN, Patel R, Paterson DL, Arias CA, Bonomo RA, Chambers HF, Fowler VG Jr, Satlin MJ, van Duin D, Doi Y; Multi-Drug Resistant Organism Network Investigators. Wang M, et al. Among authors: doi y. Clin Infect Dis. 2024 Feb 17;78(2):248-258. doi: 10.1093/cid/ciad556. Clin Infect Dis. 2024. PMID: 37738153 Free PMC article.
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study.
Wang M, Earley M, Chen L, Hanson BM, Yu Y, Liu Z, Salcedo S, Cober E, Li L, Kanj SS, Gao H, Munita JM, Ordoñez K, Weston G, Satlin MJ, Valderrama-Beltrán SL, Marimuthu K, Stryjewski ME, Komarow L, Luterbach C, Marshall SH, Rudin SD, Manca C, Paterson DL, Reyes J, Villegas MV, Evans S, Hill C, Arias R, Baum K, Fries BC, Doi Y, Patel R, Kreiswirth BN, Bonomo RA, Chambers HF, Fowler VG Jr, Arias CA, van Duin D; Multi-Drug Resistant Organism Network Investigators. Wang M, et al. Among authors: doi y. Lancet Infect Dis. 2022 Mar;22(3):401-412. doi: 10.1016/S1473-3099(21)00399-6. Epub 2021 Nov 9. Lancet Infect Dis. 2022. PMID: 34767753 Free PMC article.
Response to RMED-D-22-00,258.R1.
Ohno Y, Aoyagi K, Arakita K, Doi Y, Kondo M, Banno S, Kasahara K, Ogawa T, Kato H, Hase R, Kashizaki F, Nishi K, Kamio T, Mitamura K, Ikeda N, Nakagawa A, Fujisawa Y, Taniguchi A, Ikeda H, Hattori H, Murayama K, Toyama H. Ohno Y, et al. Among authors: doi y. Jpn J Radiol. 2022 Aug;40(8):860-861. doi: 10.1007/s11604-022-01308-8. Epub 2022 Jun 25. Jpn J Radiol. 2022. PMID: 35751793 Free PMC article. No abstract available.
2,188 results